IRIS PubliCatt

Andreotti, Felicita

Andreotti, Felicita  

ROMA - Dipartimento di Scienze cardiovascolari e pneumologiche  

Mostra records
Risultati 1 - 20 di 138 (tempo di esecuzione: 0.04 secondi).
Data di pubblicazione Titolo Autore(i) File
1-gen-2025 Direct oral anticoagulants for ventricular thrombus resolution: pilot trials show reassuring efficacy and safety compared to warfarin Andreotti, Felicita; Burzotta, Francesco
1-gen-2024 How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review Parrini, Iris; Lucà, Fabiana; Rao, Carmelo Massimiliano; Cacciatore, Stefano; Riccio, Carmine; Grimaldi, Massimo; Gulizia, Michele Massimo; Oliva, Fabrizio; Andreotti, Felicita
1-gen-2024 Letter by Andreotti et al Regarding Article, "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance" Andreotti, Felicita; Burzotta, Francesco; Maggioni, Aldo Pietro
1-gen-2024 Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition Andreotti, Felicita; Massetti, Massimo; Montalescot, Gilles
1-gen-2023 Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis Andreotti, Felicita; Geisler, Tobias; Collet, Jean-Philippe; Gigante, Bruna; Gorog, Diana A; Halvorsen, Sigrun; Lip, Gregory Y H; Morais, Joao; Navarese, Eliano Pio; Patrono, Carlo; Rocca, Bianca; Rubboli, Andrea; Sibbing, Dirk; Storey, Robert F; Verheugt, Freek W A; Vilahur, Gemma
1-gen-2023 Current concepts in coronary artery revascularisation Gaudino, Mario Fulvio Luigi; Andreotti, Felicita; Kimura, T
1-gen-2023 Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation D'Amario, Domenico; Galli, Mattia; Cappannoli, Luigi; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; Riccioni, Maria Elena; Vergallo, Rocco; A Montone, Rocco; Conte, Amelia; Meleo, Emiliana; Lancellotti, Stefano; Sacco, Monica; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo
1-gen-2023 Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension Anker, S. D.; Usman, M. S.; Anker, M. S.; Butler, J.; Bohm, M.; Abraham, W. T.; Adamo, M.; Chopra, V. K.; Cicoira, M.; Cosentino, F.; Filippatos, G.; Jankowska, E. A.; Lund, L. H.; Moura, B.; Mullens, W.; Pieske, B.; Ponikowski, P.; Gonzalez-Juanatey, J. R.; Rakisheva, A.; Savarese, G.; Seferovic, P.; Teerlink, J. R.; Tschope, C.; Volterrani, M.; von Haehling, S.; Zhang, J.; Zhang, Y.; Bauersachs, J.; Landmesser, U.; Zieroth, S.; Tsioufis, K.; Bayes-Genis, A.; Chioncel, O.; Andreotti, Felicita; Agabiti-Rosei, E.; Merino, J. L.; Metra, M.; Coats, A. J. S.; Rosano, G. M. C.
1-gen-2023 PCI for Ischemic Left Ventricular Dysfunction Andreotti, Felicita; Chiariello, Giovanni Alfonso; Massetti, Massimo
1-gen-2023 PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection Navarese, E. P.; Podhajski, P.; Gurbel, P. A.; Grzelakowska, K.; Ruscio, E.; Tantry, U.; Magielski, P.; Kubica, A.; Niezgoda, P.; Adamski, P.; Junik, R.; Przybylski, G.; Pilaczynska-Cemel, M.; Rupji, M.; Specchia, G.; Pinkas, J.; Gajda, R.; Gorog, D. A.; Andreotti, Felicita; Kubica, J.
1-gen-2023 Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation Verheugt, Freek W A; Huber, Kurt; Clemmensen, Peter; Collet, Jean-Philippe; Cuisset, Thomas; Andreotti, Felicita
1-gen-2022 [Screening for atrial fibrillation: facts and challenges] Andreotti, Felicita; Maggioni, Aldo Pietro; Massetti, Massimo
1-gen-2022 Antiplatelet Therapy during the First Year after Acute Coronary Syndrome in a Contemporary Italian Community of over 5 Million Subjects Calabria, Silvia; Andreotti, Felicita; Ronconi, Giulia; Dondi, Letizia; Campeggi, Alice; Piccinni, Carlo; Pedrini, Antonella; Esposito, Immacolata; Addesi, Alice; Martini, Nello; Maggioni, Aldo Pietro
1-gen-2022 Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention Galli, M.; Laborante, Renzo; Andreotti, Felicita; Vergallo, Rocco; Montone, Rocco Antonio; Iaconelli, A.; Trani, Carlo; Burzotta, Francesco; Crea, Filippo; D'Amario, D.
1-gen-2022 Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity Andreotti, Felicita; Maggioni, A. P.
1-gen-2022 Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity Andreotti, Felicita; Maggioni, Aldo Pietro
1-gen-2022 Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS Andreotti, Felicita; Massetti, Massimo; Ten Berg, Jurrien
1-gen-2022 Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies Iervolino, Adelaide; Spadafora, Luigi; Spadaccio, Cristiano; Iervolino, Valentina; Biondi Zoccai, Giuseppe; Andreotti, Felicita
1-gen-2022 Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials Ortega-Paz, L; Galli, M; Capodanno, D; Franchi, Francesca; Rollini, F; Bikdeli, B; Mehran, R; Montalescot, G; Gibson, Cm; Lopes, Rd; Andreotti, Felicita; Angiolillo, Dj
1-gen-2021 Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 1, Domenico D'Amario; Galli, Mattia; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; Cappannoli, Luigi; Riccioni, Maria Elena; Giuseppina Annetta, Maria; Di Stefano, Gaetano; Piccinni, Carlo; Vergallo, Rocco; Antonio Montone, Rocco; Maria Leone, Antonio; Niccoli, Giampaolo; Sabatelli, Mario; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo